Pfizer announced Thursday that the U.S. government has signed a deal to purchase 10 million courses of the company's Covid-19 pill.
Pfizer will sell 10 million courses of Covid-19.
The images are from the same source.
Pfizer said that the US will spend $5.3 billion on Paxlovid if it is approved by the FDA.
Pfizer will deliver the courses later this year and complete the order in 2022.
The deal adds to a growing U.S. arsenal of new therapies that experts feel could mark a turning point in the Pandemic.
Regulators are expected to review molnupiravir at the end of November, after the U.S. signed two deals with Ridgeback Biotherapeutics.
The government agreed to buy a million doses of the AstraZeneca cocktail, which is said to reduce the risk of death or severe Covid-19 and also protect against the symptoms of the disease.
Continue watching after the ad Visit the Advertiser website.
The face of the Covid-19 epidemic could be changed by the use of oral antivirals. Pfizer said Paxlovid can slash the risk of hospitalization or death from Covid-19 by 89% if taken shortly after the start of symptoms. The U.K. became the first country in the world to approve molnupiravir on an emergency basis. Both companies have signed deals to share the poll with low income nations and ramp up production, as a key constraining factor.
The U.S. has a $1 billion deal for extra dose of the anti-viral covid pill.
Pfizer says its Covid Pill reduced the risk of hospitalization and death.
Pfizer signs a deal with low income nations to share its anti-viral pill.
The new drugs mark a turning point in the covid-19 epidemic.
Coverage and live updates on the coronaviruses.
